Similar Search Results

A comparative analysis of domiciliary oxygen therapy in five European countries

Garattini, Livio; Cornago, Dante; Tediosi, Fabrizio - In: Health Policy 58 (2001) 2, pp. 133-149

Persistent link: https://www.econbiz.de/10005508996

Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis

Garattini, Livio; Cornago, Dante; De Compadri, Paola - In: Health Policy 82 (2007) 3, pp. 330-339

Persistent link: https://www.econbiz.de/10005516130

Pharmaceutical policy in Italy

Garattini, Livio; Cornago, Dante - In: The European Journal of Health Economics 7 (2006) 2, pp. 89-90

Persistent link: https://www.econbiz.de/10005167126

Direct medical costs unequivocally related to diabetes in Italian specialized centers

Garattini, Livio; Chiaffarino, Francesca; Cornago, Dante; … - In: The European Journal of Health Economics 5 (2004) 1, pp. 15-21

Persistent link: https://www.econbiz.de/10009404295

Pharmaceutical policy in Italy: towards a structural change?

Ghislandi, Simone; Krulichova, Iva; Garattini, Livio - In: Health Policy 72 (2005) 1, pp. 53-63

Persistent link: https://www.econbiz.de/10005516291

The German experience in reference pricing

Giuliani, Giovanni; Selke, Gisbert; Garattini, Livio - In: Health Policy 44 (1998) 1, pp. 73-85

Persistent link: https://www.econbiz.de/10005516771

A comparative analysis of generics markets in five European countries

Garattini, Livio; Tediosi, Fabrizio - In: Health Policy 51 (2000) 3, pp. 149-162

Persistent link: https://www.econbiz.de/10005520452

Should we really worry about “launch delays” of new drugs in OECD countries?

Garattini, Livio; Ghislandi, Simone - In: The European Journal of Health Economics 8 (2007) 1, pp. 1-3

Persistent link: https://www.econbiz.de/10005391156

Off-patent drugs in Italy

Garattini, Livio; Ghislandi, Simone - In: The European Journal of Health Economics 7 (2006) 1, pp. 79-83

Persistent link: https://www.econbiz.de/10005391169

Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?

Garattini, Livio; van de Vooren, Katelijne; Curto, … - In: Health Policy 119 (2015) 2, pp. 212-216

Trastuzumab (TR), a monoclonal antibody approved by EMA in 2000 and one of the first examples of “targeted therapy”, is indicated to treat human epidermal growth factor receptor 2 (HER2) positive breast cancer. TR, whose patent will expire in 2015 in Europe, has been judged positively for...

Persistent link: https://www.econbiz.de/10011190167